Sana Biotechnology/$SANA
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Ticker
$SANA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
194
ISIN
US7995661045
Website
SANA Metrics
BasicAdvanced
$623M
-
-$0.88
1.79
-
Price and volume
Market cap
$623M
Beta
1.79
52-week high
$7.40
52-week low
$1.26
Average daily volume
3.9M
Financial strength
Current ratio
3.4
Quick ratio
3.158
Long term debt to equity
37.455
Total debt to equity
43.674
Profitability
EBITDA (TTM)
-199.493
Management effectiveness
Return on assets (TTM)
-23.84%
Return on equity (TTM)
-71.44%
Valuation
Price to book
2.98
Price to tangible book (TTM)
67.22
Price to free cash flow (TTM)
-2.909
Free cash flow yield (TTM)
-34.38%
Free cash flow per share (TTM)
-94.89%
Growth
Earnings per share change (TTM)
-42.39%
3-year earnings per share growth (CAGR)
-7.82%
What the Analysts think about SANA
Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
Bulls say / Bears say
Sana Biotechnology reported positive 12-week clinical results in their type 1 diabetes study, demonstrating that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression can overcome immune recognition and function effectively. (sana.com)
The company is enrolling patients in the GLEAM trial for SC291 targeting B-cell mediated autoimmune diseases and the VIVID trial for SC262 in relapsed/refractory B-cell malignancies, with expectations to report clinical data from both studies in 2025. (sana.com)
Sana appointed Dr. Dhaval Patel as Executive Vice President and Chief Scientific Officer, bringing extensive experience in drug development, which could enhance the company's research and development capabilities. (sana.com)
Sana reported a net loss of $49.4 million for Q1 2025, indicating ongoing financial challenges. (sana.com)
The company's cash, cash equivalents, and marketable securities decreased from $152.5 million at the end of 2024 to $104.7 million by March 31, 2025, suggesting a significant cash burn rate. (sana.com)
Sana's research and development expenses for Q1 2025 were $37.2 million, reflecting substantial ongoing investment without corresponding revenue generation. (sana.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SANA Financial Performance
Revenues and expenses
SANA Earnings Performance
Company profitability
SANA News
AllArticlesVideos
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
GlobeNewsWire·2 weeks ago
Sana Biotechnology to Present at June 2025 Investor Conferences
GlobeNewsWire·3 weeks ago
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sana Biotechnology stock?
Sana Biotechnology (SANA) has a market cap of $623M as of June 20, 2025.
What is the P/E ratio for Sana Biotechnology stock?
The price to earnings (P/E) ratio for Sana Biotechnology (SANA) stock is 0 as of June 20, 2025.
Does Sana Biotechnology stock pay dividends?
No, Sana Biotechnology (SANA) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Sana Biotechnology dividend payment date?
Sana Biotechnology (SANA) stock does not pay dividends to its shareholders.
What is the beta indicator for Sana Biotechnology?
Sana Biotechnology (SANA) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.